Compare Stocks

→ $21,000 in profits in six weeks? (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZRX AzurRx BioPharma	$2.60	$4.04	$3.36 ▼ $26.30	$24.25M	1.51	628,703 shs	95,153 shs
CYCC Cyclacel Pharmaceuticals	$2.07 +3.5%	$2.18	$1.30 ▼ $13.20	$2.73M	0.54	659,292 shs	260,871 shs
EYEG AB Corporate Bond ETF	$35.12 +0.2%	$1.90	$1.44 ▼ $8.18	$24.59M	0.13	935,975 shs	2 shs
FBRX Forte Biosciences	$0.72 +1.4%	$0.71	$0.38 ▼ $1.11	$26.24M	0.46	31,132 shs	11,555 shs
OHRP OHR Pharmaceutical	$0.41 +2.5%	$7.37	$1.60 ▼ $6.28	$1.16M	0.84	180,228 shs	157,654 shs

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZRX AzurRx BioPharma	0.00%	-5.11%	-34.34%	-49.51%	-6.47%
CYCC Cyclacel Pharmaceuticals	+3.50%	+52.21%	-1.43%	-17.53%	-73.47%
EYEG AB Corporate Bond ETF	+0.18%	+0.76%	-0.21%	-1.34%	+1,701.12%
FBRX Forte Biosciences	+0.83%	-0.69%	+3.02%	+21.99%	-31.43%
OHRP OHR Pharmaceutical	+1.26%	-1.96%	+2.45%	-38.79%	+121.80%

$21,000 in profits in six weeks? (Ad)

On Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.

Click here for details.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	1.7119 of 5 stars	3.3	3.0	0.0	0.0	2.9	0.0	0.6
EYEG AB Corporate Bond ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	3.1586 of 5 stars	3.3	4.0	0.0	0.0	2.4	2.5	1.3
OHRP OHR Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	2.50	Moderate Buy	$11.00	431.40% Upside
EYEG AB Corporate Bond ETF	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	2.50	Moderate Buy	$2.75	281.94% Upside
OHRP OHR Pharmaceutical	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest AZRX, OHRP, FBRX, EYEG, and CYCC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/3/2024	CYCC Cyclacel Pharmaceuticals	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $11.00
4/8/2024	FBRX Forte Biosciences	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$2.75

(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	($0.76) per share	N/A
CYCC Cyclacel Pharmaceuticals	$420K	6.51	N/A	N/A	$0.57 per share	3.63
EYEG AB Corporate Bond ETF	$10K	2,458.53	N/A	N/A	$1.26 per share	27.87
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$0.97 per share	N/A
OHRP OHR Pharmaceutical	N/A	N/A	N/A	N/A	$3.86 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZRX AzurRx BioPharma	-$32.67M	-$11.50	N/A	N/A	N/A	N/A	-482.96%	-258.47%	N/A
CYCC Cyclacel Pharmaceuticals	-$22.56M	-$27.22	N/A	N/A	N/A	N/A	-448.19%	-151.29%	5/9/2024 (Estimated)
EYEG AB Corporate Bond ETF	-$8.09M	-$1.68	N/A	N/A	N/A	N/A	-104.96%	-60.03%	N/A
FBRX Forte Biosciences	-$31.48M	-$1.04	N/A	N/A	N/A	N/A	-94.27%	-81.36%	5/20/2024 (Estimated)
OHRP OHR Pharmaceutical	-$13.23M	N/A	0.00	∞	N/A	N/A	-75.46%	-71.18%	N/A

Latest AZRX, OHRP, FBRX, EYEG, and CYCC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/19/2024	Q4 2023	CYCC Cyclacel Pharmaceuticals	-$6.35	-$6.23	+$0.12	-$6.23	N/A	$0.03 million
3/18/2024	Q4 2023	FBRX Forte Biosciences	N/A	-$0.04	-$0.04	-$0.04	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EYEG AB Corporate Bond ETF	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
OHRP OHR Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Latest AZRX, OHRP, FBRX, EYEG, and CYCC Dividends

Announcement	Company	Period	Amount	Ex-Dividend Date	Record Date	Payable Date
4/30/2024	EYEG AB Corporate Bond ETF	Monthly	$0.1484	5/1/2024	5/2/2024	5/7/2024
3/28/2024	EYEG AB Corporate Bond ETF	Monthly	$0.1572	4/1/2024	4/2/2024	4/5/2024
2/29/2024	EYEG AB Corporate Bond ETF	Monthly	$0.1486	3/1/2024	3/4/2024	3/7/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZRX AzurRx BioPharma	N/A	1.33	1.33
CYCC Cyclacel Pharmaceuticals	N/A	0.91	0.91
EYEG AB Corporate Bond ETF	0.01	3.07	3.07
FBRX Forte Biosciences	N/A	10.45	10.45
OHRP OHR Pharmaceutical	N/A	3.73	3.73

Ownership

Institutional Ownership

Company	Institutional Ownership
AZRX AzurRx BioPharma	6.27%
CYCC Cyclacel Pharmaceuticals	23.58%
EYEG AB Corporate Bond ETF	64.16%
FBRX Forte Biosciences	77.63%
OHRP OHR Pharmaceutical	10.70%

Insider Ownership

Company	Insider Ownership
AZRX AzurRx BioPharma	7.30%
CYCC Cyclacel Pharmaceuticals	8.47%
EYEG AB Corporate Bond ETF	58.20%
FBRX Forte Biosciences	10.53%
OHRP OHR Pharmaceutical	12.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AZRX AzurRx BioPharma	12	9.33 million	8.65 million	Not Optionable
CYCC Cyclacel Pharmaceuticals	2,018	1.32 million	1.21 million	Optionable
EYEG AB Corporate Bond ETF	14	700,000	5.28 million	Not Optionable
FBRX Forte Biosciences	9	36.44 million	32.61 million	Optionable
OHRP OHR Pharmaceutical	3	2.83 million	N/A	Not Optionable

AZRX, OHRP, FBRX, EYEG, and CYCC Headlines

Source	Headline
	Pharmaceutical Stocks benzinga.com - April 14 at 8:00 AM
	CYCC Cyclacel Pharmaceuticals, Inc. seekingalpha.com - March 17 at 4:20 PM
	Sun Pharmaceutical Industries Ltd. moneycontrol.com - February 3 at 8:52 AM
	AI Advances Pharmaceutical Packaging Inspection designnews.com - May 22 at 9:22 AM
	The OHRP and SUPPORT — Another View nejm.org - April 21 at 3:16 PM
	Working at the Smithsonian si.edu - February 23 at 5:49 PM
	OHR Pharmaceutical (OHRP) is now in Oversold Territory ca.finance.yahoo.com - September 12 at 11:29 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AzurRx BioPharma

NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Cyclacel Pharmaceuticals

NASDAQ:CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

AB Corporate Bond ETF

NASDAQ:EYEG

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

Forte Biosciences

NASDAQ:FBRX

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

OHR Pharmaceutical

NASDAQ:OHRP

OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial